Roivant Sciences Ltd (ROIV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $28.64B
Last updated: Nov 17, 2026 at 4:15 PM ET
Roivant Sciences Ltd (ROIV) Statistics
Roivant Sciences (ROIV) has a market cap of $28.64B and an enterprise value of $27.00B. It kept -939.03% of revenue as net income over the last 12 months. Revenue grew 102.09% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 5.73% below the market cap, as cash exceeds debt.
| Market Cap | $28.64B |
|---|---|
| Enterprise Value | $27.00B |
| Latest price (Nov 17, 2026) | $38.71 |
Key Dates
| Last Earnings Date | Nov 9, 2026 |
|---|---|
| Fiscal Year End | March |
Valuation Ratios
Sales and book value multiples are 681.0x and 7.0x. Its year-end P/S ranged from 110.8x to 612.8x from 2021 to 2024.
| P/S Ratio | 681.0x |
|---|---|
| Forward P/S | 173.3x |
| P/B Ratio | 7.0x |
Price Statistics
The stock is up 90.78% over 52 weeks and trades 3.72% above its 50-day average.
| Beta (1Y) | 1.12 |
|---|---|
| 52-Week Change | +90.78% |
| 1-Month Change | +11.56% |
| 3-Month Change | +3.50% |
| 6-Month Change | +37.22% |
| 5-Year Change | +364.86% |
| Total Return (1Y) | +90.78% |
| Total Return (3Y CAGR) | +62.79% |
| Total Return (5Y CAGR) | +36.69% |
| Return vs SPY (1Y) | +77.09% |
| Max Drawdown (1Y) | -20.23% |
| Max Drawdown (3Y) | -28.56% |
| Sharpe Ratio (1Y) | 1.39 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $37.32 |
| 200-Day Average | $32.48 |
| 52-Week Range | $19.96 to $42.50 |
| RSI (14 Days) | 53.5 |
| Average Volume (20 Days) | 8.97M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 15.56x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 15.56x |
|---|---|
| Quick Ratio | 15.56x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -9.60% over the last 12 months, against a 5-year average of -19.53%.
| Return on Equity (ROE) | -9.60% |
|---|---|
| Return on Assets (ROA) | -7.75% |
| ROE (5Y Average) | -19.53% |
| ROA (5Y Average) | -7.47% |
| ROIC (5Y Average) | -46.54% |
| Asset Turnover | 0.01x |
Scores
ROIV has an Altman Z-Score of 44.45, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 44.45 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $41.08M over the last 12 months.
| Revenue | $41.08M |
|---|---|
| Revenue Growth (YoY) | +102.09% |
| Gross Profit | $37.89M |
| Operating Income | -$557.96M |
| Pretax Income | -$297.18M |
| Net Income | -$385.77M |
| Reported EPS (TTM) | -$1.31 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 80.72% of the $4.98B in total assets.
| Cash and Equivalents | $1.64B |
|---|---|
| Total Debt | $0 |
| Net Cash | $1.64B |
| Net Cash Per Share | $2.27 |
| Working Capital | $4.08B |
| Shareholder Equity | $4.02B |
| Book Value Per Share | $5.56 |
| Total Assets | $4.98B |
| Total Liabilities | $380.10M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $6.82M of capital spending, operating cash flow left -$43.21M of free cash flow.
| Operating Cash Flow | -$36.39M |
|---|---|
| Capital Expenditures | $6.82M |
| Free Cash Flow | -$43.21M |
| FCF Per Share | -$0.06 |
| Depreciation and Amortization | $28.77M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1358.15%.
| Gross Margin | 92.23% |
|---|---|
| Operating Margin | -1358.15% |
| Pretax Margin | -723.38% |
| Net Margin | -939.03% |
| FCF Margin | -105.18% |
Growth
Revenue fell 36.01% a year over 3 years.
| Revenue Growth (3Y CAGR) | -36.01% |
|---|---|
| Revenue Growth (5Y CAGR) | -19.07% |
| Book Value Per Share Growth (2Y CAGR) | -13.41% |
| Tangible Book Per Share Growth (2Y CAGR) | -13.41% |
Dividends and Yields
ROIV does not pay a dividend. Its free cash flow yield is -0.15%.
| FCF Yield | -0.15% |
|---|---|
| Buyback Yield | 0.71% |
| Shareholder Yield | 0.71% |
Peer Position
Against 10 similar companies, ROIV has the highest P/S.
P/S RatioPeer median 14.7x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.48%
| P/S Ratio | 681.0x vs 14.7x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +102.09% vs +13.48% median |
Analyst Forecast
Consensus estimates put revenue growth at 714.10% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +714.10% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ROIV
What is ROIV's market cap?
Roivant Sciences has a market cap of $28.64B. Its enterprise value, which adds debt and subtracts cash, is $27.00B.
How many shares of ROIV are outstanding?
Roivant Sciences has 722.75M shares outstanding. The count is up 6.14% from a year earlier.
Does ROIV pay a dividend?
No. Roivant Sciences does not pay a dividend.
How much debt does ROIV have?
Roivant Sciences has $0 of total debt and $1.64B of cash and equivalents, a net cash position of $1.64B.
ROIV pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors